Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).
Quick A, Zvinovski F, Hudson C, Hundley A, Evans C, Suresh A, Stephens J, Carpenter K, Ramaswamy B, Reinbolt R, Noonan A, VanDeusen J, Wesolowski R, Stover D, Williams N, Sardesai S, Smith K, Faubion S, Loprinzi C, Lustberg M. Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC). Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.34_suppl.202.Peer-Reviewed Original ResearchVaginal Assessment ScaleSerious adverse eventsFractional CO2 laser therapyCO2 laser therapyFemale Sexual Function IndexUrogenital Distress InventoryVaginal drynessBC survivorsBreast cancerLaser therapyStudy treatmentSingle-arm feasibility studySecondary efficacy endpointsFinal efficacy analysisSexual Function IndexER/PRFractional CO2 laser treatmentFractional CO2 laserEndocrine therapySham laserEfficacy endpointFSFI scoreAdverse eventsGenitourinary syndromePrimary efficacyImplementing Liquid Biopsies in Clinical Trials
Lustberg M, Stover D, Chalmers J. Implementing Liquid Biopsies in Clinical Trials. The Cancer Journal 2018, 24: 61-64. PMID: 29601331, PMCID: PMC5880324, DOI: 10.1097/ppo.0000000000000309.Peer-Reviewed Original ResearchConceptsClinical trialsLiquid biopsyReal-time biopsySurrogate efficacy endpointsTreatment response evaluationMultiple clinical trialsRoutine clinical practiceCell-free DNATumor-specific biomarkersEfficacy endpointBlood markersPredictive biomarkersPharmacodynamic biomarkersPrognostic biomarkerTreatment selectionTumor markersBiopsyClinical practiceDisease statusTumor cellsResponse evaluationAdditional studiesBiomarkersTrialsExtracellular vesicles